[go: up one dir, main page]

WO2010088000A3 - Antifibrotic compounds and uses thereof - Google Patents

Antifibrotic compounds and uses thereof Download PDF

Info

Publication number
WO2010088000A3
WO2010088000A3 PCT/US2010/000287 US2010000287W WO2010088000A3 WO 2010088000 A3 WO2010088000 A3 WO 2010088000A3 US 2010000287 W US2010000287 W US 2010000287W WO 2010088000 A3 WO2010088000 A3 WO 2010088000A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
antifibrotic compounds
antifibrotic
subclasses
classes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/000287
Other languages
French (fr)
Other versions
WO2010088000A2 (en
Inventor
Itzhak D. Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elicio Therapeutics Inc
Original Assignee
Angion Biomedica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angion Biomedica Corp filed Critical Angion Biomedica Corp
Publication of WO2010088000A2 publication Critical patent/WO2010088000A2/en
Publication of WO2010088000A3 publication Critical patent/WO2010088000A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides compounds having formula (I), (II) and (III): F and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and where anti-fibrotic activity is beneficial.
PCT/US2010/000287 2009-02-02 2010-02-02 Antifibrotic compounds and uses thereof Ceased WO2010088000A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20661509P 2009-02-02 2009-02-02
US61/206,615 2009-02-02
US21474409P 2009-04-28 2009-04-28
US61/214,744 2009-04-28

Publications (2)

Publication Number Publication Date
WO2010088000A2 WO2010088000A2 (en) 2010-08-05
WO2010088000A3 true WO2010088000A3 (en) 2011-04-07

Family

ID=42396268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/000287 Ceased WO2010088000A2 (en) 2009-02-02 2010-02-02 Antifibrotic compounds and uses thereof

Country Status (1)

Country Link
WO (1) WO2010088000A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34305A (en) 2011-09-01 2013-04-30 Novartis Ag DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
EA026368B1 (en) 2011-12-21 2017-03-31 Новира Терапьютикс, Инк. Hepatitis b antiviral agents
HUE046368T2 (en) * 2012-01-26 2020-02-28 Angion Biomedica Corp Antifibrotic compounds and uses thereof
SG11201501359TA (en) 2012-08-28 2015-03-30 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
CA2899706C (en) 2013-02-28 2021-10-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulfamoyl pyrolamide derivatives and their use as medicines to treat hepatitis B
DK3024819T3 (en) 2013-07-25 2018-06-06 Janssen Sciences Ireland Uc GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
AU2014338947B2 (en) 2013-10-23 2018-02-22 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (en) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Combination therapy for treatment of hbv infections
PL3102572T3 (en) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
CN107847762A (en) 2015-03-19 2018-03-27 诺维拉治疗公司 Azacyclooctane and azacyclononane derivatives and methods of treating hepatitis B infection
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017059059A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
SG10202011827YA (en) 2016-04-15 2021-01-28 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
EP3765011A1 (en) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
KR20210130753A (en) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Amide derivatives useful for the treatment of HBV infection or HBV-induced disease
EP3966205A1 (en) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063330A2 (en) * 2003-01-06 2004-07-29 Osi Pharmaceuticals, Inc. (2-carboxamido) (3-amino) thiophene compounds
US20050154014A1 (en) * 2003-01-06 2005-07-14 Jason Bloxham (2-carboxamido)(3-amino) thiophene compounds
US20060074082A1 (en) * 2004-09-17 2006-04-06 Arlindo Castelhano (Arylamidoaryl)cyanoguanidine compounds
WO2006070878A1 (en) * 2004-12-28 2006-07-06 Astellas Pharma Inc. Carboxylic acid derivative or salt thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063330A2 (en) * 2003-01-06 2004-07-29 Osi Pharmaceuticals, Inc. (2-carboxamido) (3-amino) thiophene compounds
US20050154014A1 (en) * 2003-01-06 2005-07-14 Jason Bloxham (2-carboxamido)(3-amino) thiophene compounds
US20060074082A1 (en) * 2004-09-17 2006-04-06 Arlindo Castelhano (Arylamidoaryl)cyanoguanidine compounds
WO2006070878A1 (en) * 2004-12-28 2006-07-06 Astellas Pharma Inc. Carboxylic acid derivative or salt thereof

Also Published As

Publication number Publication date
WO2010088000A2 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
WO2011153192A3 (en) Cytochrome p450 inhibitors and uses thereof
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
MX2011012122A (en) Thiophene derivatives.
WO2010084115A3 (en) Antiviral agents
WO2012116290A3 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
HK1198869A1 (en) Combination treatments for hepatitis c
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
MX2009013501A (en) Piperidine compounds and uses thereof.
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
WO2011097946A8 (en) Oxazolidinone compounds containing ring-fused bicyclic ring, preparation method and use thereof
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX362830B (en) Therapeutic or prophylactic agent for biliary diseases.
WO2008074833A3 (en) Compounds
MX2012013879A (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases.
WO2011009714A3 (en) Benzoquinolizinium salt derivatives as anticancer agents
WO2010121675A3 (en) Thiazolyl-benzimidazoles
WO2013019091A3 (en) A COMPOUND FOR INHIBITING 11β-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10736165

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10736165

Country of ref document: EP

Kind code of ref document: A2